Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Cancer Res. Author manuscript; available in PMC 2011 February 15.
Published in final edited form as:
PMCID: PMC2822899

Krüppel-like transcription factor 11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells


Uterine leiomyoma is the most common tumor of the female genital tract and the leading cause of hysterectomy. While progesterone stimulates proliferation of uterine leiomyoma cells, the mechanism of progesterone action is not well understood. We used chromatin immunoprecipitation (ChIP)-cloning approach to identify progesterone receptor (PR) target genes in primary uterine leiomyoma smooth muscle cells. We identified 18 novel PR-binding sites, one of which was located 20.5-kb upstream of the transcriptional start site of the Krüppel -like transcription factor 11 (KLF11) gene. KLF11 mRNA levels were minimally down-regulated by progesterone but robustly up-regulated by the progesterone antagonist RU486. Luciferase reporter assays demonstrated significant baseline and RU486-inducible promoter activity in the KLF11 basal promoter or distal PR-binding region, both of which contained multiple Sp1-binding sequences but lacked classic progesterone response elements. RU486 stimulated recruitment of Sp1, RNA polymerase II, PR, and the coactivators SRC-1 and SRC-2 to the distal region and basal promoter. siRNA knockdown of PR increased KLF11 expression, while knockdown of KLF11 increased leiomyoma cell proliferation and abolished the anti-proliferative effect of RU486. In vivo, KLF11 expression was significantly lower in leiomyoma tissues compared with adjacent myometrial tissues. Taken together, using a ChIP-cloning approach, we uncovered KLF11 as an integrator of PR signaling and proliferation in uterine leiomyoma cells.

Keywords: progesterone receptor, PR target genes, chromatin immunoprecipitation, Krüppel -like transcription factor 11, uterine leiomyoma


Uterine leiomyomata are the most common gynecologic tumors in women of reproductive age. Growing evidence from basic and clinical studies indicates that progesterone and the progesterone receptor (PR) play key roles in uterine leiomyoma growth and development (1). Several investigators have shown an increased concentration of both PR isoforms (PR-A and PR-B) in leiomyoma tissue compared with adjacent myometrium (2, 3). Mitotic activity in leiomyoma tissue was also increased relative to the adjacent myometrial tissue during the luteal phase and after treatment with medroxyprogesterone acetate (4, 5).

Progesterone suppresses apoptosis and stimulates proliferation of leiomyoma cells in culture, whereas PR modulators inhibit proliferation and induce apoptosis (611). Indeed, RU486 and asoprisnil were shown to reduce leiomyoma volume (12, 13), and antiprogestins have been used as a therapeutic option for patients with leiomyomata (1). Taken together, these findings suggest that progesterone plays an important role in leiomyoma growth; however, the underlying cellular and molecular mechanisms responsible for the pathologic and therapeutic roles of progesterone and its antagonists in uterine leiomyoma are not well understood.

Progesterone-regulated gene expression is mediated by nuclear receptors PR-A and PR-B. Only a few cis-elements targeted directly by PR have been identified to date. For example, progesterone response elements (PRE) have been identified within the basal promoter regions of the progesterone-regulated genes pepsinogen C, c-myc, insulin-like growth factor binding protein-1 and MUC1 (1417). However, the basal promoters of several other progesterone-responsive target genes lack PREs, including PR, p21, p27, glycodelin and the folate receptor type α; these promoters contain Sp1 sites that appear essential for PR-mediated transcription in in vitro reporter assays (1822). Recently, chromatin immunoprecipitation (ChIP)-cloning and ChIP-on-chip approaches have successfully identified a large number of ERα-binding sites at significant distances from the transcriptional start sites of estradiol-regulated genes (2326). A similar genome-wide binding pattern of PR and consequent regulation of human genes via distant binding sites have been suspected but not yet shown.

To better understand the effects of progesterone on human uterine leiomyoma growth, we sought to identify a larger number of PR target genes. We used a ChIP-cloning strategy for unbiased identification of regulatory targets of progesterone/PR in leiomyoma. Interestingly, among the cloned targets, endogenous PR was found to bind in intact cells to a region located 20.5-kb upstream of the transcriptional start site of the Krüppel -like transcription factor 11 (KLF11) gene. Here, we report that this region may interact with the basal KLF11 promoter via recruitment of common transcription factors in response to the antiprogestin RU486. We also demonstrated a potential role for KLF11 in protecting against leiomyoma growth and mechanism for the therapeutic action of antiprogestins.

Materials and Methods

Tissue collection and cell culture

Human uterine leiomyoma and matched myometrium were collected from 56 premenopausal women undergoing hysterectomy, following the protocol approved by the Institutional Review Board for Human Research of Northwestern University. The subjects had not received any hormonal treatment during the 6 months prior to surgery. The leiomyoma smooth muscle (LSM) cells were cultured as previously described (27). Cells used in these experiments were passaged one or two times.

ChIP and ChIP-cloning

We performed the ChIP-cloning procedure as described previously except that the chromatin fragments were immunoprecipitated using anti-PR antibody (Abcam, Cambridge, MA) (25). Antibodies used for standard ChIP included anti-phosphorylated RNA PolII, anti-Sp1, anti-SRC-2 (Abcam), and anti-SRC-1 (Santa Cruz Biotechnology, Santa Cruz, CA). Primers used for ChIP on SLC7A8 and SOX8 are available upon request. Primers used for ChIP at the 20.5-kb upstream of KLF11 transcription start site were 5′-GCATGATAGTTTCTTGGGTCAACC-3′ (forward), 5′-GTAGGCGATGCTATAGTCCACAG-3′ (reverse). Real-time PCR primers used for fold-enrichment of distal regulatory sites were identical, and real-time PCR primers for basal promoter region were 5′-GGTCAAGGACGCATTCCTAA-3′ (forward), 5′-GAGAGGGGACCACGCTTATAG-3′ (reverse). In this instance, real-time PCR was performed using ABI SYBR Green Master kit (ABI, Foster City, CA).

RNA preparation and real-time quantitative PCR

Total RNA from LSM cells and tissues of leiomyoma and matched myometrium was extracted using Tri-reagent (Sigma-Aldrich, St. Louis, MO). CDNA was prepared with Superscript III first-Strand Synthesis System (Invitrogen, Carlsbad, CA). KLF11, SOX8, SLC7A8, PR and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA were amplified by real-time PCR using the ABI TaqMan Gene Expression system (ABI) and the ABI 7900 Sequence Detection System. All gene expression was normalized to GAPDH.

Plasmids, transfectioin, and luciferase assays

PR-binding region (−19,369-bp/−21,192-bp) identified by ChIP cloning for KLF11 was amplified by PCR using primers 5′-ATGAGGGACCAACTCGGGAAATGG-3′ (forward), 5′-GGAGGACAACAGGACACTGACTTT-3′ (reverse), and cloned into the pGL3 promoter vector (Promega). The proximal 5′-flanking region (−549-bp/+171-bp) was amplified by PCR using primers 5′-ATGTCACCTAGAACCG-3′ (forward), 5′-CGTGTGCATCGTGCAG-3′ (reverse), and cloned into the pGL3 basic vector (Promega).

T47D cells (ATCC, Manassas, VA) were transfected with 2 μg reporter plasmid and 0.2 μg PRL-TK-Luc using Fugene HD transfection reagent (Roche, Indianapolis, IN). Twenty-four hours after transfection, cells were treated with vehicle (ethanol) or RU486 (10−6 M) for 48 hours, and cell extracts were prepared using passive lysis buffer (Promega). Illustrated results are normalized to PRL-TK-Luc using a dual luciferase reporter assay system (Promega).

Immunostaining for bromo-2-deoxyuridine (BrdU)

The effect of KLF11 on cell proliferation was determined by BrdU incorporation assay as described previously except that BrdU (20 μM) was added during the final 4 hours of cell treatment (28). The result was expressed as the BrdU labeling index (percentage of BrdU-labeled cells in total cells counted).

Small interfering RNA (siRNA)

To knockdown the expression of endogenous PR and KLF11, LSM cells were transfected with PR siRNA or KLF11 siRNA (Dharmacon, Chicago, IL) using Lipofectamine RNAiMAX (Invitrogen). Nontargeting control siRNA (Dharmacon) was transfected as a negative control.


Cell lysates were analyzed by immunoblotting as described previously (29) using monoclonal anti-PR (kindly provided by Dr. Edwards, Baylor College of Medicine, Houston, Texas), anti-KLF11 (Abcam), and anti-proliferating cell nuclear antigen (PCNA) (GenScript Corp., Piscataway, NJ) antibodies. Equal loading was confirmed using anti-β-actin antibody (Sigma-Aldrich). The intensity of bands was quantified using ImageJ software.

Statistical analysis

Differences between groups were analyzed by the student’s t-test or one-way ANOVA analysis followed by Fisher’s protected least significance difference test. Significance was accepted at P<0.05.


Identification of PR genomic targets in human LSM cells

To identify regulatory regions that recruit PR within the entire genome of human LSM cells, we performed ChIP using anti-PR antbody in LSM cells treated with progesterone for 1 hour. Twenty-one cloned fragments were mapped to the genome. Among these, 17 fragments were localized within an intron of a gene; two fragments were located 5′ or 3′ to the most proximally located genes; and the other two fragments were mapped to an exon of a gene. Because two genomic regions were associated with multiple ChIP fragments, a total of 18 novel PR-binding sites were identified (Supplemental Table S1).

These PR-binding sites were distributed genome-wide to chromosomes 1, 2, 5, 7, 10, 14, 15, 16, 17, 19 and 20 (Supplemental Figure S1). Interestingly, binding sites were not distributed evenly between the chromosomes. For example, four binding sites were located on chromosome 1 and two sites were located on each of chromosomes 7, 14, 17 and 20, whereas no binding to eleven chromosomes was noted, suggesting specificity for genomic distribution.

Of the 18 novel sites, we identified the 16 genes that had a PR-binding site within an intron or an exon. We also identified a pair of the most proximal genes that flanked each of the remaining two PR-binding sites (Supplemental Table S1). One binding site was located 5′-upstream of both KLF11 and AILT5830, which are transcribed in opposite directions, whereas the remaining binding site was 3′-downstream of both SOX8 and FLJ32252 genes, also transcribed in opposite directions (Supplemental Table S1).

We next selected eleven well-characterized genes from Supplemental Table S1 and investigated their progesterone responsiveness. We treated LSM cells for 2 and 4 hours with progesterone in the presence or absence of the progesterone antagonist RU486 and measured mRNA levels. Treatment with progesterone in the presence or absence of RU486 altered mRNA levels in 5 of 11 (45%) genes (Supplemental Table S2). In particular, we observed that SLC7A8 mRNA levels were increased after progesterone treatment reaching statistical significance at 4 hours (Figure 1A). This increase was blocked by RU486. SLC7A8 encodes a key amino acid transporter protein that may be an important regulator of leiomyoma growth (30). SOX8 mRNA levels were not affected by progesterone, but were down-regulated significantly at 2 hours in the presence of RU486 (Figure 1A). SOX8 encodes a transcription factor that inhibits skeletal muscle differentiation (31).

Figure 1
(A) Modulation of selected PR target gene expression by progesterone. LSM cells were treated with vehicle (ethanol) and progesterone (10−6 M) in the presence or absence of progesterone antagonist RU486 (10−4 M) for 2 and 4 hours. SLC7A8, ...

Conversely, KLF11 mRNA levels were slightly but significantly down-regulated by progesterone treatment. However, they were robustly and significantly increased by 2.3-fold at 2 hours and 3.3-fold at 4 hours in the presence of RU486 (Figure 1A). Similarly, mRNA levels of the genes PRDM16 and MAN1C1 were up-regulated by RU486 (Supplemental Table S2). As shown in Supplemental Table S1, PRDM16 encodes a transcription factor that may play an important role in the leukemogenic transformation of the cells (32), whereas MAN1C1 plays an important role in N-glycan biosynthesis (33).

The mild but significant down-regulation of KLF11 by progesterone was also observed independently in a gene microarray experiment using the Illumina platform; progesterone treatment for 4 hours down-regulated KLF11 mRNA by 16.5% (P<0.05, data not shown). We also showed that R5020, a synthetic progesterone agonist, significantly decreased KLF11 mRNA level about 30% (Figure 1B). R5020 induced a more robust reduction in KLF11 mRNA levels compared with progesterone (Figure 1B).

These results suggested that the distant PR-binding modules were functionally active and differentially modulated progesterone and antiprogestin responsiveness of the genes identified in the ChIP cloning screen. We next confirmed the recruitment of PR to the distant PR-binding sites of three selected genes, SLC7A8, SOX8 and KLF11, and further investigated whether these sites interacted with RNA PolII using a conventional ChIP assay. Independent pools of immunoprecipitated chromatin fragments from LSM cells treated with progesterone for 1 hour were analyzed. As shown in Figure 1C, PR and RNA PolII were recruited to PR-binding sites in the SLC7A8, SOX8, and KLF11 genes.

Regulation of KLF11 mRNA and protein levels by RU486 in LSM cells

RU486 and other antiprogestins have been shown to reduce leiomyoma size in a number of clinical trials (12, 13). Mechanisms responsible for this therapeutic effect are unknown. KLF11 is a known tumor suppressor (34) and was significantly up-regulated in the presence of RU486 as shown in Figure 1A. Therefore, we focused our investigation on KLF11 regulation and function in LSM cells as a possible mediator of the therapeutic effects of antiprogestins on uterine leiomyoma. Cells were treated with different doses of RU486 (10−10 − 10−6 M) for 6 hours and KLF11 mRNA levels were determined. As shown in Figure 2A, RU486 (10−8 − 10−6 M) significantly induced KLF11 expression. RU486 10−6 M also stimulated comparable increases in KLF11 protein levels after 72 hours of treatment (Figure 2B).

Figure 2
Regulation of KLF11 mRNA and protein levels by RU486 and PR in LSM cells. (A) KLF11 mRNA levels were determined from LSM cells treated with vehicle or the indicated concentrations of RU486 for 6 hours. The asterisks on the columns (10−8, 10−7 ...

Next, we knocked down endogenous PR using siRNA in order to establish a functional role for PR in mediating KLF11 expression in LSM cells. Transfection of LSM cells with PR siRNA reduced PR mRNA and protein levels (Figure 2C). PR knockdown increased KLF11 mRNA by 2.1-fold compared with control siRNA-transfected cells (Figure 2D).

Stimulation of KLF11 promoter activity by RU486

To determine whether the novel PR-binding region identified by ChIP cloning confers promoter activity, we cloned this fragment (−19,369-bp/−21,192-bp) into the pGL3 promoter vector. To determine whether the proximal 5′-flanking region of KLF11 gene was also involved in RU486-regulated gene transcription, the −549-bp/+171-bp sequence was cloned into the pGL3 basic vector. Individual constructs were transfected into T47D breast cancer cells because this cell line with high levels of endogenous PR could be transfected reproducibly with both vectors (21). As shown in Figure 3A, the 1,823-bp fragment bearing the distal PR-binding region demonstrated significant promoter enhancing activity in the absence or presence of RU486. The basal promoter region also conferred significant transcriptional activity that was induced by RU486 (Figure 3B). These results indicated that both the distal region and basal promoter of the KLF11 gene have transcriptional regulatory activity.

Figure 3
Transcriptional activity of the distal PR-binding region and the basal promoter of the KLF11 gene. The distal PR-binding region was cloned into the pGL3 promoter vector and the basal promoter region was cloned into the pGL3 basic vector. T47D breast cancer ...

Recruitment of transcription factors and steroid receptor coactivators to KLF11 basal promoter and distal PR-binding region

As the PR-binding region is located 20.5-kb upstream of the KLF11 transcription start site, we sought to elucidate whether this distal region was associated with the basal transcriptional multimeric complex. There did not appear to be any classic, palindromic PRE consensus sequences in either the basal promoter or the 20.5-kb distal PR-binding region. However, we found several half PREs in the distal region and several GC-rich Sp1 sites in both regions, and hypothesized that ligand-bound PR may associate with Sp1 and regulate KLF11 expression by mediating an interaction between the distal and basal regulatory sites. To test this hypothesis, we designed primers flanking the basal promoter and the distal region. We then evaluated simultaneous recruitment of RNA PolII, Sp1 and PR to the distal PR-binding region and the basal promoter of KLF11 using real-time PCR.

We also characterized whether RU486 stimulated KLF11 expression through recruiting coactivators to its basal promoter and the distal PR-binding region. It was reported that PR action selectively required the steroid receptor coactivator SRC-3 in breast; but in contrast, it required SRC-1 as a coactivator in uterus (35). SRC-1 and SRC-2 have a similar pattern of expression that is distinct from the pattern of expression of SRC-3, indicating that these two proteins play cooperative roles in regulating steroid hormone action in the murine uterus (36). We thus evaluated the recruitment of SRC-1 and SRC-2 to KLF11 basal promoter and the distal regulatory region.

In the basal promoter region, RU486 significantly increased the association of RNA PolII, Sp1, PR (Figure 4A), SRC-1, and SRC-2 (Figure 4B) with this region of the KLF11 gene. In the distal regulatory region, however, RU486 significantly induced the recruitment of only SRC-2 to this region (Figure 4B). We observed trends that RU486 enhanced the interaction of RNA PolII, Sp1, PR, and SRC-1 to the distal regulatory region, but none of them reached statistical significance (Figures 4A and 4B).

Figure 4
Association of transcription factors and steroid receptor coactivators with the distal PR-binding region and the basal promoter of the KLF11 gene. LSM cells were exposed to RU486 (10−6 M) or vehicle (ethanol) for 1 hour. DNA interaction with transcription ...

To further verify that PR is necessary for the recruitment of transcriptional complexes, we determined the effects of PR knockdown on SRC-2 recruitment in the presence or absence of RU486. As expected, RU486 induction of PR recruitment to both the distal region and the basal promoter was abolished by PR siRNA (data not shown). PR knockdown significantly reduced the baseline recruitment of SRC-2 to the distal region, but didn’t cause significant change of its association with the basal promoter region (Figure 4C). RU486-induced SRC-2 recruitment to the basal promoter was decreased robustly by about 2.4-fold in the presence of PR siRNA, whereas PR siRNA strikingly decreased RU486-induced SRC-2 binding to the distal region by about 7-fold (Figure 4C).

These data suggest that RU486 regulates KLF11 expression via simultaneous recruitment of PR, its coactivators and general transcription factors to its basal promoter and distal regulatory region. These findings also suggest that the distal PR-binding region regulates KLF11 expression through an interaction with the basal transcriptional multimeric complex.

Knockdown of KLF11 is associated with increased LSM proliferation

We performed knockdown of endogenous KLF11 to investigate how it may be involved in progesterone- or RU486-regulated LSM cell proliferation, as indicated by PCNA level and the rate of BrdU incorporation. Real-time PCR analysis confirmed that KLF11 siRNA reduced endogenous KLF11 expression by approximately 80% (Figure 5A). As shown in Figure 5B, KLF11 siRNA or the pure progesterone agonist R5020 decreased KLF11 protein levels and increased PCNA levels. In contrast, RU486 decreased PCNA levels, and knockdown of KLF11 blunted this inhibitory effect (Figure 5C). Alterations in LSM cell proliferation were verified by the BrdU incorporation assay. Figure 5D illustrates that RU486 significantly decreased the BrdU labeling index from 7.1% to 3.8%. Knockdown of KLF11 increased the BrdU labeling index to 17.6% (P<0.01, compared with vehicle treated and control siRNA transfected cells), even in the presence of RU486 (16.3%). These results suggest that regulation of LSM cell proliferation by progesterone agonists or antagonists may be mediated, at least in part, by KLF11.

Figure 5
Regulation of LSM cell proliferation by KLF11. (A) LSM cells were mock transfected (without siRNA) or transfected with control siRNA or KLF11 siRNA for 48 hours, then KLF11 mRNA expression levels were detected using real-time PCR and standardized to GAPDH ...

KLF11 expression in leiomyoma and matched myometrial tissues

To understand the in vivo relevance of progesterone and antiprogestin regulated KLF11 expression in leiomyoma, we analyzed mRNA and protein levels of KLF11 in human leiomyoma and matched adjacent normal myometrial tissues using real-time PCR and western blot. KLF11 mRNA levels in 17 subjects were lower in leiomyoma than in myometrial tissues, and only one subject had higher KLF11 mRNA levels in leiomyoma compared with myometrial tissues. As shown in Figure 6A, the mean expression level of KLF11 in leiomyoma tissues was approximately half of that of matched myometrial tissues (n=18, P<0.001). Similarly, mean KLF11 protein level was significantly lower in leiomyoma than matched myometrial tissues from 6 subjects (Figure 6B).

Figure 6
mRNA and protein levels of KLF11 in human leiomyoma and matched myometrial tissues. (A) 36 samples from 18 subjects were analyzed for mRNA; 18 samples were obtained from leiomyomas and 18 from adjacent myometrial tissues. To allow comparisons of data ...


A significant volume of work has focused on identifying estrogen receptor binding sites using computational genomics (3739), promoter microarrays (26), CpG island libraries (40), ChIP cloning (25, 26) and ChIP-on-chip methods (24). Although progesterone has important and complex effects on the female reproductive tract, comparatively little is known about genome-wide PR-binding sites. Using ChIP-cloning technology and progesterone-responsive primary leiomyoma cells, we identified 18 novel PR-binding sites, which corresponded to 20 genes proximal to these sites. Specifically, we showed that RU486 enhanced recruitment of PR, its coactivators SRC-1 and SRC-2, as well as key general transcription factors RNA PolII and Sp1, to both distal PR-binding region and basal promoter of the KLF11 gene and induced its expression. We also found that KLF11 is a robust suppressor of leiomyoma growth.

We did not identify any PR-binding sites within a basal promoter. Five percent of PR-binding sequences were located in far distal 5′-regions, 5% were in 3′-regions, and 80% of binding sites lay within an intron of a gene. Considering that introns comprise approximately 40% of the genome, this suggests a higher affinity of PR to coding regions of its target genes. This is consistent with our previous findings indicating that 46% of ERα binding sites were located within an intron of a gene in breast cancer cells (25).

None of the reported PR target genes was pulled out in this study (1422). Some unavoidable limitations of the current ChIP cloning strategy such as, the affinity of the antibody used to pull down chromatin and the on-and-off interaction pattern of transcription factors with DNA may cause the incomplete cloning of all target genes (25, 26, 41, 42). The low endogenous PR levels in cultured LSM cells may also account for the low number of PR-binding sites cloned in this study (43).

Regulation of half of the genes located proximately to these distant PR-binding sites by progesterone or RU486 suggested that these sequences are functionally active. PR-binding fragments located distal to genes or within introns might function through long-range interactions that involve looping of chromatin to bring the regulatory elements within the proximity of basal promoters.

Both proximal and distal regulatory regions of the KLF11 gene recruited not only PR and Sp1, but also RNA PolII upon RU486 treatment. Various models have been proposed to explain how a distal enhancer communicates with a proximal promoter: the looping, the tracking, and the linking models (44, 45). With regard to the distal-proximal communication of the KLF11 gene, our data support a looping model. We plan to use a chromosome conformation capture assay to investigate whether the KLF11 distal region and proximal promoter physically interact in intact cells.

RU486 stimulated the basal promoter activity but not the enhancer function of the distal region. RU486 also enhanced PR binding to the basal promoter but not to the distal region. The distal region, however, exhibits significant basal enhancer function, basal PR binding activity and RU486-induced SRC-2 recruitment, which is PR-dependent (Figure 4C). Taken together, these findings are suggestive that the distal PR binding site’s major function is the stabilization of the RU486/PR-dependent enhancer complex at the KLF11 promoter. It appears that an interaction between the basal promoter and the distal PR binding region would be necessary for RU486-dependent regulation of KLF11 expression.

We found that, at least for the target genes studied here, RU486 was a much more robust regulator compared with progesterone. Knockdown of PR or treatment with RU486 significantly increased KLF11 expression, whereas the native progesterone hormone minimally suppressed its expression. The synthetic progesterone agonist R5020, however, markedly suppressed KLF11 level (Figure 1B and and5B).5B). The difference between the effects of progesterone and R5020 may be due to possible rapid metabolization of progesterone in these cells.

Consistent with the notion that coactivators play major roles in determining PR activity (46), we found that, through interacting with PR, RU486 enhanced the binding of SRC-1 and SRC-2 to the basal promoter and the distal PR-binding region, which gave rise to gene induction. RU486 function as an inducer of gene transcription is not without precedent. Shatnawi et al demonstrated that RU486 can stimulate expression of genes encoding folate receptor type α, p21 and p27 in a specific promoter context that has G/C-rich Sp1 binding elements but no classical PRE sites (22). In line with this observation, we found that both distal PR-binding region and the basal promoter of the KLF11 gene, with multiple G/C-rich Sp1 binding sites in both regions, could recruit PR. Additionally, our data suggest that the biological activity of PR liganded by mixed antagonist/agonist compounds is complex and may depend on the promoter context and the availability of coregulators.

KLF11 is a transcription factor that serves as a downstream effector of TGFβ-dependent signaling. It is down-regulated in human cancers, inhibits cell growth in vitro and in vivo, and inhibits neoplastic transformation (34). Consistent with these reports, we found that KLF11 expression was significantly down-regulated in leiomyoma tissues compared with adjacent matched myometrial tissues. Moreover, KLF11 inhibited LSM cell growth. While the mechanism involved in KLF11-regulated cell proliferation needs to be further clarified, our studies provide an initial insight into the mechanism by which progesterone or RU486 regulates leiomyoma growth and development. Given that progesterone exerts a number of essential functions in inhibition of estrogen-dependent endometrial carcinogenesis and promotion of breast cancer development, it is tempting to explore the regulation and function of KLF11 in these malignancies (4749).

In summary, using an unbiased approach, we uncovered KLF11 as a novel PR target responsive to progesterone antagonist RU486 in LSM cells. KLF11 mediated the anti-proliferative effects of RU486 in leiomyoma cells. These studies reveal a potential mechanism underlying the modulation of progesterone- and antiprogestin-regulated differentiation and proliferation in LSM cells. The PR-dependent down-regulation of KLF11 expression in LSM cells may represent a missing link in steroid signaling pathways that explains the pathogenesis of uterine leiomyoma. Furthermore, the identification of direct targets of KLF11 will be important to elucidate its role in uterine leiomyoma biology.

Supplementary Material


This work was supported by National Institutes of Health Grant HD46260 to Dr. Serdar E Bulun


1. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005;26:423–38. [PubMed]
2. Kovacs KA, Lengyel F, Kornyei JL, et al. Differential expression of Akt/protein kinase B, Bcl-2 and Bax proteins in human leiomyoma and myometrium. J Steroid Biochem Mol Biol. 2003;87:233–40. [PubMed]
3. Brandon DD, Bethea CL, Strawn EY, et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol. 1993;169:78–85. [PubMed]
4. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol. 1989;160:637–41. [PubMed]
5. Tiltman AJ. The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol. 1985;4:89–96. [PubMed]
6. Matsuo H, Maruo T, Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab. 1997;82:293–9. [PubMed]
7. Maruo T, Matsuo H, Shimomura Y, et al. Effects of progesterone on growth factor expression in human uterine leiomyoma. Steroids. 2003;68:817–24. [PubMed]
8. Chegini N, Ma C, Tang XM, Williams RS. Effects of GnRH analogues, ‘add-back’ steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod. 2002;8:1071–8. [PubMed]
9. Xu Q, Takekida S, Ohara N, et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab. 2005;90:953–61. [PubMed]
10. Chen W, Ohara N, Wang J, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab. 2006;91:1296–304. [PubMed]
11. Sasaki H, Ohara N, Xu Q, et al. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab. 2007;92:616–23. [PubMed]
12. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006;108:1381–7. [PubMed]
13. Chwalisz K, DeManno D, Garg R, Larsen L, Mattia-Goldberg C, Stickler T. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin Reprod Med. 2004;22:113–9. [PubMed]
14. Balbin M, Lopez-Otin C. Hormonal regulation of the human pepsinogen C gene in breast cancer cells. Identification of a cis-acting element mediating its induction by androgens, glucocorticoids, and progesterone. J Biol Chem. 1996;271:15175–81. [PubMed]
15. Moore MR, Zhou JL, Blankenship KA, Strobl JS, Edwards DP, Gentry RN. A sequence in the 5′ flanking region confers progestin responsiveness on the human c-myc gene. J Steroid Biochem Mol Biol. 1997;62:243–52. [PubMed]
16. Gao J, Mazella J, Suwanichkul A, Powell DR, Tseng L. Activation of the insulin-like growth factor binding protein-1 promoter by progesterone receptor in decidualized human endometrial stromal cells. Mol Cell Endocrinol. 1999;153:11–7. [PubMed]
17. Brayman MJ, Julian J, Mulac-Jericevic B, Conneely OM, Edwards DP, Carson DD. Progesterone receptor isoforms A and B differentially regulate MUC1 expression in uterine epithelial cells. Mol Endocrinol. 2006;20:2278–91. [PubMed]
18. Tang M, Mazella J, Gao J, Tseng L. Progesterone receptor activates its promoter activity in human endometrial stromal cells. Mol Cell Endocrinol. 2002;192:45–53. [PubMed]
19. Gao J, Mazella J, Seppala M, Tseng L. Ligand activated hPR modulates the glycodelin promoter activity through the Sp1 sites in human endometrial adenocarcinoma cells. Mol Cell Endocrinol. 2001;176:97–102. [PubMed]
20. Gizard F, Robillard R, Gervois P, et al. Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene. FEBS Lett. 2005;579:5535–41. [PubMed]
21. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB. Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem. 1998;273:10696–701. [PubMed]
22. Shatnawi A, Tran T, Ratnam M. R5020 and RU486 act as progesterone receptor agonists to enhance Sp1/Sp4-dependent gene transcription by an indirect mechanism. Mol Endocrinol. 2007;21:635–50. [PubMed]
23. Carroll JS, Liu XS, Brodsky AS, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 2005;122:33–43. [PubMed]
24. Carroll JS, Meyer CA, Song J, et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet. 2006;38:1289–97. [PubMed]
25. Lin Z, Reierstad S, Huang CC, Bulun SE. Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. Cancer Res. 2007;67:5017–24. [PubMed]
26. Laganiere J, Deblois G, Giguere V. Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells. Mol Endocrinol. 2005;19:1584–92. [PubMed]
27. Rossi MJ, Chegini N, Masterson BJ. Presence of epidermal growth factor, platelet-derived growth factor, and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinology. 1992;130:1716–27. [PubMed]
28. Duan C, Bauchat JR, Hsieh T. Phosphatidylinositol 3-kinase is required for insulin-like growth factor-I-induced vascular smooth muscle cell proliferation and migration. Circ Res. 2000;86:15–23. [PubMed]
29. Deb S, Zhou J, Amin SA, et al. A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I. 3 and II by disrupting a transcriptional complex in breast adipose fibroblasts. J Biol Chem. 2006;281:2585–97. [PubMed]
30. Bassi MT, Sperandeo MP, Incerti B, et al. SLC7A8, a gene mapping within the lysinuric protein intolerance critical region, encodes a new member of the glycoprotein-associated amino acid transporter family. Genomics. 1999;62:297–303. [PubMed]
31. Schmidt K, Glaser G, Wernig A, Wegner M, Rosorius O. Sox8 is a specific marker for muscle satellite cells and inhibits myogenesis. J Biol Chem. 2003;278:29769–75. [PubMed]
32. Mochizuki N, Shimizu S, Nagasawa T, et al. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood. 2000;96:3209–14. [PubMed]
33. Tremblay LO, Herscovics A. Characterization of a cDNA encoding a novel human Golgi alpha 1, 2-mannosidase (IC) involved in N-glycan biosynthesis. J Biol Chem. 2000;275:31655–60. [PubMed]
34. Fernandez-Zapico ME, Mladek A, Ellenrieder V, Folch-Puy E, Miller L, Urrutia R. An mSin3A interaction domain links the transcriptional activity of KLF11 with its role in growth regulation. Embo J. 2003;22:4748–58. [PubMed]
35. Han SJ, DeMayo FJ, Xu J, Tsai SY, Tsai MJ, O’Malley BW. Steroid receptor coactivator (SRC)-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor. Mol Endocrinol. 2006;20:45–55. [PubMed]
36. Jeong JW, Lee KY, Han SJ, et al. The p160 steroid receptor coactivator 2, SRC-2, regulates murine endometrial function and regulates progesterone-independent and -dependent gene expression. Endocrinology. 2007;148:4238–50. [PubMed]
37. Jin VX, Leu YW, Liyanarachchi S, et al. Identifying estrogen receptor alpha target genes using integrated computational genomics and chromatin immunoprecipitation microarray. Nucleic Acids Res. 2004;32:6627–35. [PMC free article] [PubMed]
38. Kamalakaran S, Radhakrishnan SK, Beck WT. Identification of estrogen-responsive genes using a genome-wide analysis of promoter elements for transcription factor binding sites. J Biol Chem. 2005;280:21491–7. [PubMed]
39. Lin CY, Strom A, Vega VB, et al. Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol. 2004;5:R66. [PMC free article] [PubMed]
40. Watanabe T, Inoue S, Hiroi H, Orimo A, Kawashima H, Muramatsu M. Isolation of estrogen-responsive genes with a CpG island library. Mol Cell Biol. 1998;18:442–9. [PMC free article] [PubMed]
41. Hestermann EV, Brown M. Agonist and chemopreventative ligands induce differential transcriptional cofactor recruitment by aryl hydrocarbon receptor. Mol Cell Biol. 2003;23:7920–5. [PMC free article] [PubMed]
42. Creekmore AL, Ziegler YS, Boney JL, Nardulli AM. Estrogen receptor alpha regulates expression of the breast cancer 1 associated ring domain 1 (BARD1) gene through intronic DNA sequence. Mol Cell Endocrinol. 2007;267:106–15. [PMC free article] [PubMed]
43. Zaitseva M, Vollenhoven BJ, Rogers PA. In vitro culture significantly alters gene expression profiles and reduces differences between myometrial and fibroid smooth muscle cells. Mol Hum Reprod. 2006;12:187–207. [PubMed]
44. Blackwood EM, Kadonaga JT. Going the distance: a current view of enhancer action. Science. 1998;281:60–3. [PubMed]
45. Bulger M, Groudine M. Looping versus linking: toward a model for long-distance gene activation. Genes Dev. 1999;13:2465–77. [PubMed]
46. Han SJ, Jeong J, Demayo FJ, et al. Dynamic cell type specificity of SRC-1 coactivator in modulating uterine progesterone receptor function in mice. Mol Cell Biol. 2005;25:8150–65. [PMC free article] [PubMed]
47. Schindler AE. Progestogen deficiency and endometrial cancer risk. Maturitas. 2009;62:334–7. [PubMed]
48. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33. [PubMed]
49. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–12. [PubMed]